SOHINI DAS

Stories by SOHINI DAS

Prices of key Covid bulk drugs shoot up as demand rises

Prices of key Covid bulk drugs shoot up as demand rises

Rediff.com   12 May 2021

The API of Paracetamol, a fever and pain medication, has grown 25 per cent from Rs 450-480 per kg in December 2020 to Rs 580-600 per kg in April. When compared to the pre-Covid prices of December 2019, the surge is much steeper -- around 140 per cent, reports Sohini Das.

With Covid surge, FabiFlu becomes most sold drug in India

With Covid surge, FabiFlu becomes most sold drug in India

Rediff.com   11 May 2021

Drugs that are used to treat Covid or used by people as immunity boosters have seen a jump in sales and, in turn, rankings.

COVID-19 second wave: Delays in RT-PCR tests

COVID-19 second wave: Delays in RT-PCR tests

Rediff.com   9 May 2021

While there is a shortage of testing kits, manpower and capacities, India does not have other scalable testing options.

'No preparedness planning, no accountability, no action plan'

'No preparedness planning, no accountability, no action plan'

Rediff.com   8 May 2021

'This government did not have any plan for safety stocks of essential medicines.'

Pharma industry posts 51.5% growth in April sales

Pharma industry posts 51.5% growth in April sales

Rediff.com   8 May 2021

When compared to the domestic sales of April 2019, the growth is around 37 per cent. However, compared to the previous month (March), the growth is 18.4 per cent.

Remdesivir black-market thrives as Covid cases rise

Remdesivir black-market thrives as Covid cases rise

Rediff.com   6 May 2021

Artificial shortages and brazen hawking of the drug on the streets at 15 times the normal price rule the day as the official machinery tries desperately to stamp out the parallel market, reports Sohini Das

Gujarat gets lion's share of Covid vaccines

Gujarat gets lion's share of Covid vaccines

Rediff.com   4 May 2021

Delhi, which has been one of the worst affected states, accounted for less than two per cent of total vaccinations in the 18-44 age-group.

Covid vaccine: Too early to say if booster dose needed

Covid vaccine: Too early to say if booster dose needed

Rediff.com   30 Apr 2021

Initial data has shown immunity triggered by the two mRNA vaccines -- Pfizer-BioNTech and Moderna -- lasts for at least six months

Covid vaccine could cost up to Rs 1000 in private market

Covid vaccine could cost up to Rs 1000 in private market

Rediff.com   28 Apr 2021

While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.

A COVID-19 Vaccine Snapshot

A COVID-19 Vaccine Snapshot

Rediff.com   28 Apr 2021

Sputnik V is already approved in India and Sinovac is unlikely to come in as it does not meet the criteria.

Where is the manpower to handle ventilators?

Where is the manpower to handle ventilators?

Rediff.com   25 Apr 2021

The second wave of the pandemic has not only crippled medical infrastructure in terms of hospital beds, but has also led to bottlenecks in invasive ventilators and medical oxygen capacities and supplies.

Demand for Covid-19 tests growing 100 pc week-on-week

Demand for Covid-19 tests growing 100 pc week-on-week

Rediff.com   23 Apr 2021

One challenge for many laboratories in ramping up is the shortage of trained manpower for collecting samples, report Sohini Das, Vinay Umarji and Virendra Singh Rawat.

Shortage of key chemical from US hits Covaxin ramp-up plans

Shortage of key chemical from US hits Covaxin ramp-up plans

Rediff.com   22 Apr 2021

'In case of shortage of other raw material, like filters and bags, one can try to develop another vendor. However, for chemicals as critical as adjuvants, this is not possible'

Serum, Bharat Biotech to get Rs 45 bn for 300 mn vaccines

Serum, Bharat Biotech to get Rs 45 bn for 300 mn vaccines

Rediff.com   20 Apr 2021

This will be an upfront payment for the vaccine doses that these two companies will supply to the government.

COVID-19 vaccine: Why Poonawalla wrote to Biden

COVID-19 vaccine: Why Poonawalla wrote to Biden

Rediff.com   17 Apr 2021

'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'

100 million Covaxin vaccines by Sept

100 million Covaxin vaccines by Sept

Rediff.com   17 Apr 2021

The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.

Second Covid wave is 1.7x times faster than first wave, shows data

Second Covid wave is 1.7x times faster than first wave, shows data

Rediff.com   15 Apr 2021

It has taken 51 days to reach a daily caseload of 84,000 from 11,000, as against 85 days taken in the first wave, report Abhishek Waghmare and Sohini Das.

'We will be prioritising vaccine only for India'

'We will be prioritising vaccine only for India'

Rediff.com   14 Apr 2021

'I don't think anybody would want to be in my position today where every head of State has to be explained that I am prioritising my country because there is a surge in cases.'

Serum, Bharat Bio seek govt funds to boost vaccine output

Serum, Bharat Bio seek govt funds to boost vaccine output

Rediff.com   5 Apr 2021

Both manufacturers have sought funds in excess of Rs 150 crore under the department of biotechnology's Mission Covid Suraksha scheme. Announced last November, the scheme has an outlay of Rs 900 crore to help develop Covid vaccines, from the clinical development stage to setting up production sites.

Expert panel seeks more data on Sputnik V Covid vaccine

Expert panel seeks more data on Sputnik V Covid vaccine

Rediff.com   2 Apr 2021

'No approval was given to Sputnik V on Thursday. Some queries have been asked on safety, efficacy, and logistics, which the firm will have answers to at the next meeting'